Synergysm of voriconazole or itraconazole with other antifungal agents against species of Fusarium

Revista Iberoamericana de Micologia

Volumn 30, Issue 3, 2013, Pages 200-204

  Spader, Tatiana B ^a   Venturini, Tarcieli P ^a   Rossato, Luana ^a   Denardi, Laura B ^a   Cavalheiro, Patricia B ^a   Botton, Sonia A ^a   Santurio, Janio M ^a   Alves, Sydney Hartz ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Antifungal agents; Fusarium spp.; Susceptibility; Synergism; Voriconazole

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; TERBINAFINE; VORICONAZOLE; NAPHTHALENE DERIVATIVE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CONCENTRATION RESPONSE; DRUG ANTAGONISM; DRUG POTENTIATION; FUNGAL STRAIN; FUNGUS ISOLATION; FUSARIUM; FUSARIUM CHLAMYDOSPORUM; FUSARIUM OXYSPORUM; FUSARIUM PROLIFERATUM; FUSARIUM SOLANI; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NUCLEOTIDE SEQUENCE; ANTIFUNGAL RESISTANCE; CLASSIFICATION; COMPARATIVE STUDY; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; SPECIES DIFFERENCE;

FUNGI; FUSARIUM; FUSARIUM CHLAMYDOSPORUM; FUSARIUM OXYSPORUM; FUSARIUM PROLIFERATUM; FUSARIUM SOLANI;

ANTIFUNGAL AGENTS; DRUG RESISTANCE, FUNGAL; DRUG SYNERGISM; FLUCYTOSINE; FUSARIUM; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; NAPHTHALENES; SPECIES SPECIFICITY; VORICONAZOLE;

EID: 84886950479     PISSN: 11301406     EISSN: 21739188     Source Type: Journal    
DOI: 10.1016/j.riam.2013.01.002     Document Type: Article

References (32)

1. Afeltra J., Vitale R.G., Mouton J.W., Verweij P.E. Potent synergistic in vitro interaction between nonantimicrobial membrane-active compounds and itraconazole against clinical isolates of Aspergillus fumigatus resistant to itraconazole. Antimicrob Agents Chemother 2004, 48:1335-1343.
2. Allendoerfer R.A., Marquis A.J., Rinaldi M.G., Graybill J.R. Combined therapy with fluconazole and flucytosine in murine cryptococal meningitis. Antimicrob Agents Chemother 1991, 35:726-729.
3. Argenta J.S., Santurio J.M., Alves S.H., Pereira D.I.B., Cavalheiro A.S., Spanamberg A., et al. In vitro activities of voriconazole, itraconazole and terbinafine alone or in combination against Pythium insidiosum isolates from Brazil. Antimicrob Agents Chemother 2008, 52:767-769.
4. Arikan S., Lozano-Chiu M., Paetznick V., Nangia S., Rex J.H. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J Clin Microbiol 1999, 37:3946-3951.
5. Azor M., Gené J., Cano J., Manikandan P., Venkapathy N., Guarro J. Less frequent Fusarium species of clinical interest: correlation between morphological and molecular identification and antifungal susceptibility. J Clin Microbiol 2009, 47:1463-1468.
6. Barchiesi F., Gallo D., Caselli F., Di Francesco L.F., Arzeni D., Giacometti A., et al. In vitro interactions of itraconazole with flucytosine against clinical isolates of Cryptococcus neoformans. J Antimicrob Chemother 1999, 44:65-70.
7. Campo M., Lewis R.E., Kontoyiannis D.P. Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998-2009. J Infect 2010, 60:331-337.
8. Cantón E., Pemán J., Gobernado M., Viudes A., Espinel-Ingroff A. Synergistic activities of fluconazole and voriconazole with terbinafine against four Candida species determined by checkerboard, time-kill, and Etest methods. Antimicrob Agents Chemother 2005, 49:1593-1596.
9. Chen S.C.A., Playford E.G., Sorrell T. Antifungal therapy in invasive fungal infections. Curr Opin Pharmacol 2010, 10:522-530.
10. Clinical Laboratory Standards, Institute Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard. Document M38-A2 2008, CLSI, Wayne, PA.
11. Córdoba S., Rodero L., Vivot W., Abrantes R., Davel G., Vitale R.G. In vitro interactions of antifungal agents against clinical isolates of Fusarium spp. Int J Antimicrob Agents 2008, 31:171-174.
12. Craven P.C., Graybill J.R. Combination of oral flucytosine and ketoconazole as therapy for experimental cryptococcal meningitis. J Infect Dis 1984, 149:584-590.
13. Dignani M.C., Anaissie E. Human fusariosis. Clin Microbiol Infect 2004, 10:67-75.
14. Dupont B., Drouhet E. In vitro synergy and antagonism of antifungal agents against yeast-like fungi. Postgrad Med J 1979, 55:683-686.
15. Evans J., Levesque D., de Lahunta A., Jensen H.E. Intracranial fusariosis: a novel cause of fungal meningoencephalitis in a dog. Vet Pathol 2004, 41:510-514.
16. Ghannoum M.A., Fu Y., Ibrahim A.S., Mortara L.A., Shafiq M.C., Edwards J.E., et al. In vitro determination of optimal antifungal combinations against Cryptococcus neoformans and Candida albicans. Antimicrob Agents Chemother 1995, 39:2459-2465.
17. Guarro J., Pujol I., Mayayo E. In vitro and in vivo experimental activities of antifungal agents against. Antimicrob Agents Chemother 1999, 43:1256-1257.
18. Johnson M.D., MacDougall C., Ostrosky-Zeichner L., Perfect J.R., Rex J.H. Combination antifungal therapy. Antimicrob Agents Chemother 2004, 48:693-715.
19. Meletiadis J., Mouton J.W., Meis J.F.G.M., Verweij P.E. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother 2003, 47:106-117.
20. Mykami Y., Takahashi A., Yazawa K., Terao K., Ueno Y. Synergistic interaction of miconazole and fluconazole at sub-MIC level on Candida albicans. Mycoses 1992, 35:321-327.
21. Nguyen M.H., Barchiesi F., McGough D.A., Lu V.L., Rinaldi M.G. In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrob Agents Chemother 1995, 39:1691-1695.
22. Nucci M., Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis 2002, 35:909-920.
23. Nucci M., Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007, 20:695-704.
24. Odds F.C. Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro. Antimicrob Agents Chemother 1982, 22:763-770.
25. O'donnell K., Sarver B.A., Brandt M., Chang D.C., Noble-Wang J., Park B.J., et al. Phylogenetic diversity and microsphere array-based genotyping of human pathogenic fusaria, including isolates from the multistate contact lens-associated US keratitis outbreaks of 2005 and 2006. J Clin Microbiol 2007, 45:2235-2248.
26. Ortoneda M., Capilla J., Javier Pastor F., Pujol I., Guarro J. In vitro interactions of licensed and novel antifungal drugs against Fusarium spp. Diagn Microbiol Infect Dis 2004, 48:69-71.
27. Polak A. Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice. Chemotherapy 1987, 33:381-395.
28. Raad I.I., Hachem R.Y., Herbrecht R., Graybill J.R., Hare R., Corcoran G., et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006, 42:1398-1403.
29. Ryder N.S., Leitner I. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species. Med Mycol 2001, 39:91-95.
30. Scheven M., Junemann K., Schramm H., Huhn W. Successful treatment of a Candida albicans sepsis with a combination of flucytosine and fluconazole. Mycoses 1992, 35:315-316.
31. Van Cutsen J. Therapy of experimental meningeal and disseminated cryptococcosis. Mycoses 1993, 36:357-367.
32. Viviani M.A., Tortorano A.M., Pagano A., Vigevani G.M., Gubertini G., Cristina S., et al. European experience with itraconazole in systemic mycosis. J Am Acad Dermatol 1990, 23:587-593.